Project Grant R21AI182432
Award Date
6/1/24
Completion Date
4/30/26
Dollars Obligated
$841K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New Orleans, LA 70112, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $689,068 to the University of Cincinnati to establish ex vivo growth systems for the fungal genus Pneumocystis, which causes a life-threatening pneumonia in immunodeficient individuals. The key objectives are to: 1) Use metabolomics and flux balance analysis to identify critical nutrients for growing the surrogate...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA 93.855 Allergy and Infectious Diseases Research, is focused on developing a molecular toolbox for the fungal pathogen Pneumocystis jirovecii. The key objectives are to establish a transformation system using CRISPR/Cas9 gene editing and plasmid-mediated approaches, which will enable functional studies on the biology and pathogenesis of Pneumocystis infection. The $402,860 award, with a...
The federal Project Grant award R21AI189268, totaling $226,500.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research conducted by the University of Rochester to investigate novel mechanisms of CD4-independent immunity against Pneumocystis pneumonia (PCP), a serious respiratory fungal infection that remains a significant health challenge for immunocompromised...
This Project Grant award of $750,815, provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), supports research aimed at developing novel anti-infective strategies to treat pulmonary mucormycosis, a deadly invasive fungal infection. The key objectives are to: 1) examine the role of the host cell hypoxia-response pathway, specifically the protein ANGPTL4, in the pathogenesis of mucormycosis and explore its therapeutic...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $781,129 to The Regents of the University of California, San Francisco (UCSF) to conduct a prospective, multicenter cohort study of 400 critically ill children with acute respiratory failure. The goal is to validate and extend an integrated host-microbe metagenomic diagnostic tool developed by the research team. This...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, will provide $2,205,213 to the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center to advance the understanding and management of mucormycosis, a lethal fungal infection. The key objectives are to decipher the immunopathogenesis of mucormycosis and use this knowledge to develop new diagnostic assays...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $119,082 to Brigham & Women's Hospital Inc. to conduct research on adaptive immunity to the fungus Aspergillus during neutropenia. The research aims to determine how neutrophils influence the development of adaptive immunity to Aspergillus, a life-threatening respiratory infection, in...
The University of Southern California (USC) received a $623,986 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The funding supports a research project to study the genetic and molecular mechanisms that enable fungi, specifically the opportunistic pathogen Saccharomyces cerevisiae, to persist and cause infections in mammalian hosts. Key objectives include: Identifying causal...
The National Cancer Institute (NCI) awarded a $1,138,458 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of Chicago to decipher the role of mycobiomes (fungal communities) in lung carcinogenesis. The 5-year research project aims to: Establish the carcinogenic effect of fungi, particularly Aspergillus fumigatus and Alternaria, on lung cancer using a novel 3D-organotypic lung (iLung) model derived from human pluripotent stem cells. Understand the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 - Allergy and Infectious Diseases Research program provides $170,000.00 to Prokaryotics Incorporated, a pharmaceutical research company, to perform structure-based design of novel antifungal inhibitors targeting the glycosylphosphatidylinositol (GPI) ethanolamine phosphate transferase, MCD4. The research aims to develop mechanistically novel antifungal agents to address...